IGM Bioscience3 Aug 2018 21:01
Death Receptor 5 (DR5)
Death Receptor 5 (DR5, TNRSF10B, TRAILR2) is a member of the TNF receptor superfamily which is displayed on the surface of tumor cells. Similar to other members of the TNF receptor superfamily, strong DR5 immunologic activity requires that three DR5 proteins on the surface of a tumor cell be bound together by a DR5 ligand or an antibody in order to send a strong biological signal. In the case of DR5, binding three or more DR5 proteins with an IgM antibody sends a strong apoptotic signal (commit suicide or programmed cell death) to the tumor cell.
DR5 is present on a broad range of solid tumors (colon, breast, prostate and pancreatic), as well as lymphomas and leukemias. A number of IgG anti-DR5 antibodies were taken into clinical trials by pharmaceutical and biotech companies and failed to show adequate efficacy. We believe that IgG anti-DR5 antibodies, which can only bind two DR5 targets, may not have been able to produce a strong enough apoptotic signal.
The multivalent binding provided by an IgM anti-DR5 agonist antibody may produce a much stronger apoptotic signal, as compared with an IgG anti-DR5 antibody. IGM Biosciences has shown that IgM anti-DR5 antibodies are much more effective in vitro and in animal models as contrasted with comparable IgG anti-DR5 antibodies.
V
Scancell Holdings plc, ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, announces that it has entered into an agreement with the University of Nottingham to acquire a number of novel monoclonal antibodies to tumour-associated glycans ("Assigned Antibodies"). Alongside this, Scancell has also acquired a proprietary technology to enable the modification of the constant region (FC) of a human antibody to allow direct tumour killing. Together these offer a complementary platform to Scancell's existing cancer immunotherapy platforms, ImmunoBody® and Moditope®.
so basically they feel that the IGm model has a better chance of binding and killing but unproven as still pre clinical
scancell is using a modified Antibody to do the killing, but has far more experience in antibodies as Immunobody is also an antibody structure which does induce high avidity
so at this stage its all "who knows" in 6 to 7 years you may have an answer C7
Sign In
Follow the stocks
